Screener
Amylyx Pharmaceuticals, Inc. AMLX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s retained earnings?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported retained earnings of -$836.13M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s retained earnings decreased by 22.2% year-over-year, from -$684.04M to -$836.13M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s retained earnings?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s retained earnings has grown at a 48.2% compound annual growth rate (CAGR), from -$155.85M to -$751.43M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude